Search
Lucid Diagnostics Inc
LUCDAdd to Watchlist
0.398USD
+0.008+2.05%
Close 11-05 16:00（ET）
76.00MMarket Cap
LossP/E TTM
Lucid Diagnostics Inc (LUCD) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Lucid Diagnostics Inc in the past month.
Buy
1 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.000USD+888.14%
LUCD Analyst Recommendation Trends
In the current month, LUCD has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LUCD average Analyst price target in the last month is 4.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
4
4
4
4
4
4
4
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
6
LUCD Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Guardant Health Inc
GH
12
14
2
0
0
28
Abbott Laboratories
ABT
11
13
4
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
12
4
0
0
21
Financial Forecasting
Based on analysts' estimates, LUCD EPS is projected to reach -0.063 in FY2026Q3, following reported EPS of -0.080 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.08
-0.07
-0.06
-0.06
Actual
-0.12
-0.17
-0.08
--
--
Surprise
-23.80%
-103.19%
-17.61%
--
--
FAQs
What is Lucid Diagnostics Inc's expected revenue for the next quarter?
Lucid Diagnostics Inc's expected revenue is 1.64M.
What is Lucid Diagnostics Inc's price target?
Analysts forecast that Lucid Diagnostics Inc's price target is USD 4.00, with the highest forecast at USD 9.50 and the lowest forecast at USD 2.00.
How have Lucid Diagnostics IncLUCD's recent earnings per share performed?
The market expectation was USD -0.08, while Lucid Diagnostics IncLUCD's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for Lucid Diagnostics Inc?
Based on the ratings of Lucid Diagnostics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.